

**Amendments to the specification:**

Please replace Example 1 that begins on page 12, line 17 and ends on page 13, line 7 with the following.

**Example 1**

(3R,6R)-3-(2,3-dihydro-1H-inden-2-yl)-1-[(1R)-1-(2-methyl-1,3-oxazol-4-yl)-2-(4-morpholinyl)-2-oxoethyl]-6-[(1S)-1-methylpropyl]-2,5-piperazinedione  
~~Diisopropylethylamine (100mg, 3.3equiv.), pyBOP (159mg, 1.3equiv.) and morpholine (102 uL, 5 equiv.) were added sequentially to a solution of (3R,6R)-3-(2,3-dihydro-1H-inden-2-yl)-6-[(1S)-1-methylpropyl]-2,5-dioxo-1-piperazinyl-(2-methyl-1,3-oxazol-4-yl)acetic acid (100mg) in dimethylformamide (2ml) and the mixture stirred for 4 days at room temperature. The reaction was diluted with dichloromethane (10ml) and 2N HCl (10ml) added. The organic phase was separated, washed with saturated sodium bicarbonate solution (10ml) dried via a frit and evaporated. The residue was purified by preparative HPLC to give (3R,6R)-3-(2,3-dihydro-1H-inden-2-yl)-1-[(1R)-1-(2-methyl-1,3-oxazol-4-yl)-2-(4-morpholinyl)-2-oxoethyl]-6-[(1S)-1-methylpropyl]-2,5-piperazinedione (9mg) as a colourless solid.~~

HPLC  $R_t$  = 2.8 minutes; m/z  $[M+H]^+$  = 495

$^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  7.72 (s, 1H), 7.26-7.15 (m, 4H), 6.93 (d, 1H), 6.30 (s, 1H), 4.18 (d, 1H), 4.06 (dd, 1H), 3.70-3.30 (m, 8H), 3.17-3.10 (m, 3H), 2.98-2.86 (m, 1H), 2.81-2.75 (m, 1H), 2.49 (s, 3H), 1.69-1.60 (m, 1H), 1.50-1.43 (m, 1H), 1.05-0.95 (m, 1H), 0.80-0.75 (m, 6H).